Amicus Therapeutics (FOLD) Stock Forecast, Price Target & Predictions
FOLD Stock Forecast
Amicus Therapeutics stock forecast is as follows: an average price target of $15.25 (represents a 27.40% upside from FOLD’s last price of $11.97) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
FOLD Price Target
The average price target for Amicus Therapeutics (FOLD) is $15.25 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $19.00 to $13.00. This represents a potential 27.40% upside from FOLD's last price of $11.97.
FOLD Analyst Ratings
According to 7 Wall Street analysts, Amicus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FOLD stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Amicus Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Tazeen Ahmad | Bank of America Securities | $15.00 | $12.03 | 24.69% | 25.31% |
| May 14, 2024 | Debjit Chattopadhyay | Guggenheim | $13.00 | $9.04 | 43.81% | 8.60% |
| May 09, 2024 | Jeffrey Hung | Morgan Stanley | $19.00 | $9.48 | 100.42% | 58.73% |
| Dec 19, 2023 | Jeffrey Hung | Morgan Stanley | $20.00 | $12.66 | 57.98% | 67.08% |
| May 10, 2021 | Salveen Richter | Goldman Sachs | $14.00 | $9.39 | 49.09% | 16.96% |
The latest Amicus Therapeutics stock forecast, released on Oct 17, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $15.00, which represents a 24.69% increase from the stock price at the time of the forecast ($12.03), and a 25.31% increase from FOLD last price ($11.97).
Amicus Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 4 |
| Avg Price Target | $15.00 | $15.00 | $16.75 |
| Last Closing Price | $11.97 | $11.97 | $11.97 |
| Upside/Downside | 25.31% | 25.31% | 39.93% |
In the current month, the average price target of Amicus Therapeutics stock is $15.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 25.31% increase as opposed to Amicus Therapeutics's last price of $11.97. This month's average price target is down 0.00% compared to last quarter, and down -10.45% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 17, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Oct 11, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 11, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Sep 06, 2024 | Jefferies | - | Buy | Initialise |
| Jul 22, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 30, 2024 | Wells Fargo | - | Overweight | Initialise |
| May 14, 2024 | UBS | Buy | Buy | Hold |
| May 14, 2024 | Guggenheim | Underperform | Underperform | Hold |
| May 14, 2024 | Guggenheim | - | Buy | Upgrade |
| May 09, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
Amicus Therapeutics's last stock rating was published by Bank of America Securities on Oct 17, 2024. The company gave FOLD a "Buy" rating, the same as its previous rate.
Amicus Therapeutics Financial Forecast
Amicus Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $103.50M | - | $86.27M | $88.10M | $81.69M | $80.73M | $78.72M | $82.15M | $79.55M | $77.41M | $66.40M | $70.57M | $67.44M |
| Avg Forecast | $258.00M | $242.00M | $229.00M | $221.00M | $222.00M | $209.00M | $197.00M | $183.00M | $184.14M | $169.19M | $154.72M | $140.84M | $145.51M | $134.93M | $121.21M | $111.19M | $114.35M | $102.30M | $89.83M | $83.05M | $86.31M | $84.21M | $85.87M | $77.18M | $83.41M | $80.11M | $73.16M | $71.70M | $69.56M | $64.81M |
| High Forecast | $258.00M | $242.00M | $229.00M | $221.00M | $222.00M | $209.00M | $197.00M | $183.00M | $184.14M | $169.19M | $154.72M | $140.84M | $145.51M | $136.59M | $121.21M | $111.19M | $114.43M | $102.30M | $89.83M | $83.05M | $86.31M | $84.21M | $85.87M | $77.18M | $83.41M | $80.11M | $73.16M | $71.70M | $69.56M | $64.81M |
| Low Forecast | $258.00M | $242.00M | $229.00M | $221.00M | $222.00M | $209.00M | $197.00M | $183.00M | $184.14M | $169.19M | $154.72M | $140.84M | $145.51M | $133.61M | $121.21M | $111.19M | $114.27M | $102.30M | $89.83M | $83.05M | $86.31M | $84.21M | $85.87M | $77.18M | $83.41M | $80.11M | $73.16M | $71.70M | $69.56M | $64.81M |
| # Analysts | 7 | 4 | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | - | 1.04% | 1.02% | 0.97% | 0.94% | 1.02% | 0.98% | 0.99% | 1.06% | 0.93% | 1.01% | 1.04% |
Amicus Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $114.35M, with a low forecast of $114.27M, and a high forecast of $114.43M. FOLD's average Quarter revenue forecast represents a 10.48% increase compared to the company's last Quarter revenue of $103.50M (Sep 23).
Amicus Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 4 | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-29.21M | - | $-39.87M | $-56.09M | $-17.79M | $-51.54M | $-66.47M | $-70.61M | $-40.79M | $-36.98M | $-54.49M | $-62.77M | $-54.00M |
| Avg Forecast | $-169.27M | $-158.77M | $-150.24M | $-145.00M | $-145.65M | $-137.12M | $-129.25M | $-120.06M | $-120.81M | $-111.01M | $-101.51M | $-92.40M | $-95.47M | $-88.52M | $-79.53M | $-80.03M | $-75.02M | $-67.12M | $-58.94M | $-63.27M | $-56.63M | $-55.25M | $-56.34M | $-57.51M | $-54.72M | $-52.56M | $-48.00M | $-52.22M | $-45.64M | $-42.52M |
| High Forecast | $-169.27M | $-158.77M | $-150.24M | $-145.00M | $-145.65M | $-137.12M | $-129.25M | $-120.06M | $-120.81M | $-111.01M | $-101.51M | $-92.40M | $-95.47M | $-87.66M | $-79.53M | $-64.03M | $-74.97M | $-67.12M | $-58.94M | $-50.61M | $-56.63M | $-55.25M | $-56.34M | $-46.01M | $-54.72M | $-52.56M | $-48.00M | $-41.77M | $-45.64M | $-42.52M |
| Low Forecast | $-169.27M | $-158.77M | $-150.24M | $-145.00M | $-145.65M | $-137.12M | $-129.25M | $-120.06M | $-120.81M | $-111.01M | $-101.51M | $-92.40M | $-95.47M | $-89.62M | $-79.53M | $-96.04M | $-75.07M | $-67.12M | $-58.94M | $-75.92M | $-56.63M | $-55.25M | $-56.34M | $-69.02M | $-54.72M | $-52.56M | $-48.00M | $-62.66M | $-45.64M | $-42.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.44% | - | 0.63% | 0.99% | 0.32% | 0.91% | 1.16% | 1.29% | 0.78% | 0.77% | 1.04% | 1.38% | 1.27% |
undefined analysts predict FOLD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Amicus Therapeutics's previous annual EBITDA (undefined) of $NaN.
Amicus Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 4 | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-21.58M | - | $-52.93M | $-55.87M | $-33.29M | $-62.16M | $-85.26M | $-83.28M | $-50.29M | $-51.23M | $-65.66M | $-71.40M | $-64.01M |
| Avg Forecast | - | - | - | - | - | - | - | - | $31.55M | $19.70M | $9.91M | $-3.25M | $4.14M | $50.12K | $-16.68M | $-94.91M | $-17.56M | $-23.05M | $-34.61M | $-75.03M | $-35.60M | $-57.33M | $-64.06M | $-68.21M | $-47.50M | $-53.38M | $-65.65M | $-62.93M | $-69.77M | $-64.52M |
| High Forecast | - | - | - | - | - | - | - | - | $31.55M | $19.70M | $9.91M | $-3.25M | $4.14M | $81.45K | $-16.68M | $-75.93M | $-2.93M | $-23.05M | $-34.61M | $-60.02M | $-35.60M | $-57.33M | $-64.06M | $-54.57M | $-47.50M | $-53.38M | $-65.65M | $-50.34M | $-69.77M | $-64.52M |
| Low Forecast | - | - | - | - | - | - | - | - | $31.55M | $19.70M | $9.91M | $-3.25M | $4.14M | $25.06K | $-16.68M | $-113.89M | $-26.35M | $-23.05M | $-34.61M | $-90.03M | $-35.60M | $-57.33M | $-64.06M | $-81.85M | $-47.50M | $-53.38M | $-65.65M | $-75.51M | $-69.77M | $-64.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | - | 0.71% | 1.57% | 0.58% | 0.97% | 1.25% | 1.75% | 0.94% | 0.78% | 1.04% | 1.02% | 0.99% |
Amicus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FOLD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Amicus Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 4 | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.65M | - | $73.96M | $54.27M | $47.27M | $53.38M | $58.12M | $57.60M | $46.11M | $42.28M | $46.73M | $43.69M | $37.85M |
| Avg Forecast | $180.54M | $169.34M | $160.24M | $154.64M | $155.34M | $146.25M | $137.85M | $128.05M | $128.85M | $118.39M | $108.26M | $98.55M | $101.82M | $94.42M | $84.82M | $64.69M | $80.01M | $71.58M | $62.86M | $51.14M | $60.40M | $58.93M | $60.09M | $46.49M | $58.36M | $56.06M | $51.19M | $44.78M | $48.67M | $45.35M |
| High Forecast | $180.54M | $169.34M | $160.24M | $154.64M | $155.34M | $146.25M | $137.85M | $128.05M | $128.85M | $118.39M | $108.26M | $98.55M | $101.82M | $95.58M | $84.82M | $77.63M | $80.07M | $71.58M | $62.86M | $61.37M | $60.40M | $58.93M | $60.09M | $55.79M | $58.36M | $56.06M | $51.19M | $53.73M | $48.67M | $45.35M |
| Low Forecast | $180.54M | $169.34M | $160.24M | $154.64M | $155.34M | $146.25M | $137.85M | $128.05M | $128.85M | $118.39M | $108.26M | $98.55M | $101.82M | $93.49M | $84.82M | $51.76M | $79.96M | $71.58M | $62.86M | $40.91M | $60.40M | $58.93M | $60.09M | $37.19M | $58.36M | $56.06M | $51.19M | $35.82M | $48.67M | $45.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | - | 1.45% | 0.90% | 0.80% | 0.89% | 1.25% | 0.99% | 0.82% | 0.83% | 1.04% | 0.90% | 0.83% |
Amicus Therapeutics's average Quarter SG&A projection for Dec 23 is $80.01M, based on 7 Wall Street analysts, with a range of $79.96M to $80.07M. The forecast indicates a 21.88% rise compared to FOLD last annual SG&A of $65.65M (Sep 23).
Amicus Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 7 | 4 | 4 | 7 | 6 | 4 | 4 | 6 | 4 | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | - | $-0.18 | $-0.19 | $-0.12 | $-0.21 | $-0.30 | $-0.31 | $-0.19 | $-0.19 | $-0.25 | $-0.28 | $-0.25 |
| Avg Forecast | - | - | - | - | - | - | - | - | $0.10 | $0.06 | $0.03 | $-0.01 | $0.01 | - | $-0.05 | $-0.06 | $-0.06 | $-0.08 | $-0.11 | $-0.14 | $-0.12 | $-0.19 | $-0.21 | $-0.25 | $-0.16 | $-0.18 | $-0.22 | $-0.24 | $-0.23 | $-0.21 |
| High Forecast | - | - | - | - | - | - | - | - | $0.10 | $0.06 | $0.03 | $-0.01 | $0.01 | - | $-0.05 | $-0.06 | $-0.01 | $-0.08 | $-0.11 | $-0.14 | $-0.12 | $-0.19 | $-0.21 | $-0.25 | $-0.16 | $-0.18 | $-0.22 | $-0.24 | $-0.23 | $-0.21 |
| Low Forecast | - | - | - | - | - | - | - | - | $0.10 | $0.06 | $0.03 | $-0.01 | $0.01 | - | $-0.05 | $-0.06 | $-0.09 | $-0.08 | $-0.11 | $-0.14 | $-0.12 | $-0.19 | $-0.21 | $-0.25 | $-0.16 | $-0.18 | $-0.22 | $-0.24 | $-0.23 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | - | 1.30% | 1.62% | 0.64% | 1.00% | 1.18% | 1.98% | 1.08% | 0.88% | 1.03% | 1.20% | 1.18% |
According to undefined Wall Street analysts, Amicus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FOLD previous annual EPS of $NaN (undefined).
Amicus Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ARVN | Arvinas | $27.04 | $75.36 | 178.70% | Buy |
| DAWN | Day One Biopharmaceuticals | $15.08 | $38.80 | 157.29% | Buy |
| MLYS | Mineralys Therapeutics | $13.88 | $30.00 | 116.14% | Buy |
| LEGN | Legend Biotech | $43.09 | $82.62 | 91.74% | Buy |
| RARE | Ultragenyx Pharmaceutical | $56.77 | $108.14 | 90.49% | Buy |
| CYTK | Cytokinetics | $54.53 | $83.23 | 52.63% | Buy |
| HRMY | Harmony Biosciences | $34.97 | $52.33 | 49.64% | Buy |
| BMRN | BioMarin Pharmaceutical | $69.47 | $103.65 | 49.20% | Buy |
| MREO | Mereo BioPharma Group | $4.56 | $6.75 | 48.03% | Buy |
| DNLI | Denali Therapeutics | $27.42 | $39.17 | 42.85% | Buy |
| KURA | Kura Oncology | $18.09 | $25.67 | 41.90% | Buy |
| FOLD | Amicus Therapeutics | $11.97 | $15.25 | 27.40% | Buy |
| EWTX | Edgewise Therapeutics | $35.51 | $45.00 | 26.72% | Buy |
| DYN | Dyne Therapeutics | $34.73 | $43.88 | 26.35% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| BPMC | Blueprint Medicines | $86.00 | $105.62 | 22.81% | Buy |
| CRNX | Crinetics Pharmaceuticals | $58.92 | $70.14 | 19.04% | Buy |
| INCY | Incyte | $66.43 | $75.63 | 13.85% | Buy |
| AGIO | Agios Pharmaceuticals | $44.14 | $48.71 | 10.35% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $50.00 | $53.83 | 7.66% | Buy |
| ARGX | argenx SE | $543.84 | $456.45 | -16.07% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
FOLD Forecast FAQ
Is Amicus Therapeutics a good buy?
Yes, according to 7 Wall Street analysts, Amicus Therapeutics (FOLD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 85.71% of FOLD's total ratings.
What is FOLD's price target?
Amicus Therapeutics (FOLD) average price target is $15.25 with a range of $13 to $19, implying a 27.40% from its last price of $11.97. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amicus Therapeutics stock go up soon?
According to Wall Street analysts' prediction for FOLD stock, the company can go up by 27.40% (from the last price of $11.97 to the average price target of $15.25), up by 58.73% based on the highest stock price target, and up by 8.60% based on the lowest stock price target.
Can Amicus Therapeutics stock reach $20?
FOLD's average twelve months analyst stock price target of $15.25 does not support the claim that Amicus Therapeutics can reach $20 in the near future.
What is Amicus Therapeutics's current price target trend?
1 Wall Street analyst forecast a $15 price target for Amicus Therapeutics (FOLD) this month, up 25.31% from its last price of $11.97. Compared to the last 3 and 12 months, the average price target increased by 25.31% and increased by 39.93%, respectively.
What are Amicus Therapeutics's analysts' financial forecasts?
Amicus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $811M (high $811M, low $811M), average EBITDA is $-532M (high $-532M, low $-532M), average net income is $0 (high $0, low $0), average SG&A $567.5M (high $567.5M, low $567.5M), and average EPS is $0 (high $0, low $0). FOLD's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $950M (high $950M, low $950M), average EBITDA is $-623M (high $-623M, low $-623M), average net income is $0 (high $0, low $0), average SG&A $664.76M (high $664.76M, low $664.76M), and average EPS is $0 (high $0, low $0).
Did the FOLD's actual financial results beat the analysts' financial forecasts?
Based on Amicus Therapeutics's last annual report (Dec 2023), the company's revenue was $399.36M, beating the average analysts forecast of $389.53M by 2.52%. Apple's EBITDA was $-195M, missing the average prediction of $-264M by -26.10%. The company's net income was $-152M, beating the average estimation of $-150M by 0.88%. Apple's SG&A was $275.27M, beating the average forecast of $265.6M by 3.64%. Lastly, the company's EPS was $-514, beating the average prediction of $-0.386 by 133057.71%. In terms of the last quarterly report (Sep 2023), Amicus Therapeutics's revenue was $103.5M, beating the average analysts' forecast of $102.3M by 1.18%. The company's EBITDA was $-29.207M, missing the average prediction of $-67.116M by -56.48%. Amicus Therapeutics's net income was $-21.577M, missing the average estimation of $-23.053M by -6.40%. The company's SG&A was $65.65M, missing the average forecast of $71.58M by -8.29%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0759 by -99.87%